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Because antithymocyte globulin (ATG) is increasingly used to prevent graft-versus-host disease (GVHD), we
performed a retrospective study in adult patients transplanted at our center between January 2008 and
December 2012 to explore incidence, characteristics, potential risk factors, and consequences of severe acute
hepatotoxicity (SAH) of rabbit ATG (Thymoglobulin) deﬁned as a grade 3 to 4 increase of transaminases. Two
hundred twelve patients were included. SAH was diagnosed in 55 patients, representing an incidence of 26%.
SAH occurred at a median time of 2 days (range, 1 to 3) after ATG administration, reaching maximum median
levels of aspartate aminotransferase and alanine aminotransferase of 8.7  upper limit of normal (ULN; range,
1.2 to 160) and 11.7  ULN (range, 4-100), respectively. The International Normalized Ratio was beyond the
normal range in 44% of patients. Transaminases decreased below 2  ULN after a median time of 9 days. We
do not report any deleterious impact of SAH on survival, nonrelapse mortality, relapse, or GVHD. Blood
systolic pressure < 90 mm Hg during administration of ATG and 2 previous autologous SCT were identiﬁed as
risk factors for SAH. We believe physicians should be aware of this common toxicity immediately after the
administration of ATG to avoid any potential hepatotoxic drug before the resolution and to prevent any risk of
hemorrhagic accident.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Antithymocyte globulin (ATG) is increasingly used before
allogeneic stem cell transplantation (allo-SCT) to reduce
incidence and severity of graft-versus-host disease (GVHD).
Randomized studies in the myeloablative setting with
unrelated donors have indeed reported reduced incidences
of grades III to IV acute and extensive chronic GVHD, without
increased relapse rates [1-4]. Unfortunately, comparable
randomized studies are lacking in the reduced-intensity
conditioning (RIC) setting. Optimal dose and schedule
remain controversial, although available retrospective data
seem to favor a dose of rabbit ATG (Thymoglobulin;
Genzyme, Lyon, France) of 4.5 to 6 mg/kg administered ondgments on page 664.
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ty for Blood and Marrow Transplantation.the last few days before transplantation [5]. Interestingly, a
large retrospective study by the Center for International
Blood and Marrow Transplant Research has challenged the
use of ATG in the RIC setting, reporting an increased relapse
risk adversely affecting overall survival (OS) [6]. These data
clearly indicate that the use of ATG itself remains a matter of
debate, at least in the RIC setting. Because of this debate, it is
important to carefully evaluate all side effects of ATG and
their potential consequences on transplant outcome.
The side effects of ATG are very common and well
described as far as fever, chills, or hypotension are concerned
[2,7]. Acute hepatotoxicity also exists, but its knowledge is
limited by the scarcity of data. One case report of reversible
acute hepatotoxicity induced by horse ATG in a patient with
Fanconi anemia undergoing allo-SCT was reported [8].
Recently, 2 cases of severe transaminases elevation have
been reported after rabbit ATG used in RIC allo-SCT [9]. Mild
and transient elevation of bilirubin levels beyond the normal
range have also been reported in 22.7% of patients after ATG
C. Médiavilla et al. / Biol Blood Marrow Transplant 21 (2015) 661e665662(Fresenius, HemoCare Immune Therapy, Gräfelﬁng, Ger-
many) without change in the level of transaminases [7].
Thus, to further explore incidence, characteristics, potential
risk factors, and consequences of acute hepatotoxicity
of ATG, we conducted a retrospective study of patients
transplanted at our center between January 2008 and
December 2012.
METHODS
Selection of Patients
All adult patients (18 years) with a ﬁrst allo-SCT performed between
January, 1, 2008 and December 31, 2012 at our center after a conditioning
regimen incorporating rabbit ATG (Thymoglobulin) were eligible. Two
hundred twelve patients fulﬁlling these criteria were included. All medical
records were reviewed to ensure the quality of data.
The doses and schedules of ATG were 2.5 mg/kg on days2 and 1 (n¼
180); 2.5 mg/kg on day 1 (n ¼ 10) or day 2 (n ¼ 13); 2.5 mg/kg on
days3, 2, and 1 (n¼ 1); and 3.75 mg/kg on days6, 5, and 4 (n¼ 8)
depending on diseases and ongoing protocols. All patients received pre-
medication with methylprednisolone (.5 mg/kg) and dexchlorpheniramine
(5 mg i.v.) 30 minutes before and 4 hours after the start of ATG. They
also received acetaminophen in case of fever, always at therapeutic doses
(4 g/day). ATG was administered over 8 to 24 hours according to tolerance.
All patients received low-dose heparin (100 UI/kg/day i.v.) and ursodeox-
ycholic acid (500 mg  3/day, p.o.) from the beginning of the conditioning
regimen for prevention of veno-occlusive disease.
During the study period, our strategy was to check liver function tests at
least 3 times a week (Monday, Wednesday, and Friday) from the start of the
conditioning regimen until discharge from hospital. Severe acute hepato-
toxicity (SAH) was deﬁned as aspartate aminotransferase (AST) and/or
alanine aminotransferase (ALT) > 5  upper limit of normal (ULN) within 1
week after administration of ATG (grade 3 or 4 toxicity according to the
Common Terminology Criteria for Adverse Events, version 4.0).
Statistical Analysis
Patient- and disease-related characteristics of both groups (SAH versus
no SAH) were compared using either the chi-square test or the Fisher test, as
appropriate. OS was calculated from the date of transplantation to either the
date of death from any cause or last follow-up. Event-free survival (EFS) was
calculated from the date of transplantation to the date of relapse, progres-
sion, death from any cause, or last follow-up. Probabilities of OS and EFS
were calculated using the Kaplan-Meier estimate [10], with the log-rank test
for univariate comparisons.
Nonrelapse mortality (NRM) included all causes of death without prior
relapse/progression, occurring at any time after transplant. Cumulative
incidence curves were used for relapse incidence and NRM in a competing
risk setting with death in complete remission as a competing event for
relapse and relapse/progression as a competing event for NRM [11].
The Gray test was used for univariate comparisons. Cumulative inci-
dence curveswere used for GVHD in a competing risks setting, with death as
a competing event. The analysis of risk factors for SAH was performed in a
Cox proportional hazards model [12] in which pretransplant variables with
P < .15 in the univariate analysis were considered and the least signiﬁcant
variables were excluded in a stepwise backward procedure until all
remaining factors were signiﬁcant at the P ¼ .05 level. For multivariate
analysis, all cases with at least 1 missing value in 1 of the variables
considered were excluded. Statistical analyses were performed with R 2.13.2
software packages (R Development Core Team, Vienna, Austria).
RESULTS
Characteristics of Patients with SAH
As shown in Table 1, SAH was diagnosed in 55 patients,
representing an incidence of 26%. The characteristics of
patients with or without SAH are summarized in Table 2.Table 1
Levels of Transaminases during or within 1 Week after Conditioning
AST and/or ALT 0 1 ULN Grade 1 > 1-3 ULN
Conditioning with ATG (n ¼ 212) 106 (50) 24 (11.3)
Conditioning without ATG* (n ¼ 198) 160 (80.8) 33 (16.7)
Values in parentheses are percents. Grades are deﬁned according to the Common
* Control group of patients transplanted during the same period of study.
y This patient had a focal nodular hyperplasia of the liver and received myeloabThe conditioning regimens of patients with SAH were ﬂu-
darabine (30 mg/m2/day for 5 days) with i.v. busulfan 0.8
mg/kg  4/day for 2 days (n ¼ 45) or 3 days (n ¼ 1) or 4 days
(n ¼ 7), cyclophosphamide (50 mg/kg/day for 4 days) with
2-Gy total body irradiation (TBI; n¼ 1), and 2-Gy TBI (n ¼ 1).
Themedian time between the ﬁrst day of ATG and SAHwas 2
days (range, 1 to 3).
Eight to 13 episodes of SAH were diagnosed each year
with different batches of ATG, excluding a batch effect. No
patient had evidence of liver involvement by hematological
disease at transplant. One female patient had chronic C
hepatitis diagnosed 9 years before allo-SCT, with undetect-
able viral load at transplant. Before administration of ATG,
transaminases were <2  ULN in 51 patients and 2 to 3 
ULN in 4 patients. No patient was receiving azoles at the time
of SAH. The maximum median levels of AST and ALT were
8.7 ULN (range,1.2 to 160) and 11.7ULN (range, 4 to 100),
respectively. There was an associated mild elevation of bili-
rubin at a median level of 1.4 ULN (range, .3 to 6.5). Further
doses of ATG were not administered in 8 patients with a
grade 4 toxicity diagnosed immediately after the ﬁrst dose.
All patients had fever and blood cultures during admin-
istration of ATG. One patient had a positive blood culture for
Enterococcus sp. No patient was diagnosed with viral hepa-
titis (A, B, C, Epstein-Barr virus, cytomegalovirus, or adeno-
virus) during SAH.
The International Normalized Ratio (INR) was >1.3 in 24
patients (median, 1.8; range, 1.32 to 3.78). In 19 patients with
grade 4 toxicity, 12 (63.1%) had an INR > 1.3 (median, 2.1;
range, 1.32 to 3.78). In the 36 patients with grade 3 toxicity,
12 (33.3%) had an INR > 1.3 (median, 1.7; range, 1.33 to 2.58).
The INR normalized in less than 1 week in all patients
without any hemorrhagic accident.
No patient developed encephalopathy or died of liver
failure. No hepatic biopsywas performed. Liver function tests
improved in all patients with both transaminases < 5 and
<2  ULN at median times of 5 days (range, 1 to 19) and 9
days (range, 3 to 22), respectively. For grade 3 toxicity, these
ﬁgureswere 2 days (range,1 to 19) and 7 days (range, 3 to 22)
and for grade 4 toxicity, 9 days (range, 6 to 15) and 15 days
(range, 10 to 20). No patient developed veno-occlusive
disease or hepatic acute GVHD. One female patient aged 59
years developed hepatic chronic GVHD 11 months after
transplant.Consequences of SAH on Transplant Outcome
In SAH versus no SAH groups, the number of primary
engraftment failures were 5 (9.1%) versus 12 (7.6%), P ¼ .77.
Median times to neutrophil engraftment to .5  109/L and
platelet engraftment to 50  109/L in SAH versus no SAH
groups were 18 days (range, 6 to 31) versus 17 days (range,10
to 40) and 13 days (range, 9 to 120) versus 13 days (range,
0 to 100), respectively.
As shown in Figure 1, with a median follow-up of 43
months (range, 11 to 76), the 3-year OS and EFS rates in SAHGrade 2 > 3-5 ULN Grade 3 > 5-20 ULN Grade 4 > 20 ULN
27 (12.7) 36 (17) 19 (9)
4 (2) 1 (.5)y 0
Terminology Criteria for Adverse Events, version 4.0.
lative conditioning with Bu-Cy.
Table 2
Characteristics of Patients with or without SAH
SAH
(n ¼ 55)
No SAH
(n ¼ 157)
P
Age, yr
Median (range) 58 (21-65) 57 (19-67)
55 38 (69.1) 93 (59.2) .26
Sex .045
Male 27 (49.1) 103 (65.6)
Female 28 (50.9) 54 (34.4)
Diseases
AML 13 (23.6) 58 (36.9) .10
ALL 3 (5.5) 9 (5.7) 1
NHL 8 (14.5) 23 (14.7) 1
HOD 5 (9.1) 6 (3.8) .16
MM 13 (23.6) 18 (11.5) .048
MDS 5 (9.1) 18 (11.5) .80
AA 1 (1.8) 7 (4.5) .68
CLL 4 (7.3) 12 (7.6) 1
MPS 3 (5.5) 6 (3.8) .70
Status at transplant
CR1 or PR1 or chronic phase 23 (41.8) 61 (38.8) .82
>CR1 or >PR1 23 (41.8) 51 (32.5) .28
Untreated 3 (5.5) 18 (11.5) .29
Refractory 6 (10.9) 27 (17.2) .37
Previous treatment with GO 2 (3.6) 2 (1.3) .28
Number of previous auto-SCT
1 18 (32.7) 41 (26.1) .44
2* 7 (12.7) 2 (1.3) .001
Median time between last auto-
SCT and allo-SCT, mo, (range)
20 (2-142) 17 (2-187)
Conditioning regimeny .03
NMA 1 (1.8) 0
RIC 46 (83.6) 113 (72)
MAC 8 (14.6) 44 (28)
Donors .49
Related 26 (47.3) 64 (40.8)
Unrelated 29 (52.7) 93 (59.2)
Female donor/male recipient 11 (20) 44 (28) .32
Source of stem cells .12
PB 54 (98.2) 144 (91.7)
BM 1 (1.8) 13 (8.3)
Number of CD34þ cells (106/kg)
Median (range) 6.3 (2.1-21.7) 6.3 (1.3-31.9)
6.3 28 (50.9) 82 (52.2) .99
Prophylaxis of GVHD
CsA 23 (41.8) 62 (39.5) .89
CsAþmethotrexate 24 (43.6) 72 (45.8) .89
CsAþMMF 8 (14.6) 22 (14) 1
MMFþsteroid 0 1 (0.7) 1
Blood systolic pressure
< 90 mm Hg during
administration of ATG
.001
Yes 22 (40) 30 (19.1)
No 18 (32.7) 93 (59.2)
Missing data 15 (27.3) 34 (21.7)
AST and/or ALT toxicity
before ATGz
.81
Grade 0 43 (78.2) 127 (80.9)
Grade 1 12 (21.8) 30 (19.1)
AML indicates acute myeloid leukemia; ALL, acute lymphoid leukemia; NHL,
non-Hodgkin lymphoma; HOD, Hodgkin disease; MM, multiple myeloma;
MDS, myelodysplastic syndrome; AA, aplastic anemia; CLL, chronic
lymphoid leukemia; MPS, myeloproliferative syndrome; CR, complete
remission; PR, partial remission; GO, gemtuzumab ozogamicin; NMA,
nonmyeloablative; MAC, myeloablative conditioning; PB, peripheral blood;
BM, bone marrow; CsA, cyclosporine A; MMF, mycophenolate mofetil.
Values in parentheses are percents, unless otherwise noted.
* Multiple myeloma (n ¼ 8) and myelodysplastic syndrome (n ¼ 1).
y According to Bacigalupo et al. Biol Blood Marrow Transplant
2009;15:1628-1633.
z According to the Common Terminology Criteria for Adverse Events,
version 4.0.
Figure 1. OS (A) and EFS (B) in SAH and no SAH groups.
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(P ¼ .1) and 49.3%  7% versus 49.7%  4% (P ¼ .65),
respectively. The 3-year NRM and relapse incidence in thesame groups were 5.4%  3.1% versus 15.6%  2.9% (P ¼ .08)
and 45.2%  7% versus 34%  3.9% (P ¼ .35), whereas the
cumulative incidence of acute GVHD grades II to IV and
extensive chronic GVHD were 21.8%  5.6% versus 36.9% 
3.9% (P¼ .052) and 10.9% 4.2% versus 15.4% 2.9% (P¼ .39),
respectively.
Risk Factors for SAH
As shown in Table 2, pretransplant characteristics of both
groups (SAH versus no SAH) were comparable except for sex,
multiple myeloma, existence of 2 previous autologous (auto-
) SCTs, conditioning regimen, blood systolic pressure < 90
mm Hg during administration of ATG, and a trend for acute
myeloid leukemia. As shown in Table 3, the multivariate
analysis identiﬁed blood systolic pressure < 90 mm Hg
during administration of ATG and the existence of 2 previous
auto-SCTs as signiﬁcant risk factors for SAH.
DISCUSSION
In the present study, the incidence of SAH after admin-
istration of ATG (Thymoglobulin) was 26%. Because ATG is
increasingly used, it is important to report such a common
toxicity. We do not report any fatal liver failure, but nearly
half of our patients had a transient increased INR. The
Table 3
Risk Factors for SAH: Multivariate Analysis
Variable Hazard
Ratio
95% Conﬁdence
Interval
P
Existence of 2 previous auto-SCTs 5.11 4.67-5.55 .0002
Systolic pressure < 90 mm Hg
during ATG
3.06 2.74-3.38 .0004
Female sex 1.48 1.15-1.82 .24
AML .65 .27-1.03 .26
RIC or NMA regimen 1.54 1.09-1.99 .34
MM 1.35 .89-1.81 .52
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deleterious impact on OS, EFS, NRM, relapse, or GVHD. The
trend for a lower incidence of acute GVHD grades II to IV in
the SAH group might be explained by higher frequencies of
related donors and RIC regimens together with a lower fre-
quency of the female donor/male recipient combination. We
also identiﬁed blood systolic pressure < 90 mm Hg during
administration of ATG and existence of 2 previous auto-SCTs
as signiﬁcant risk factors for SAH. However, because most
patients with 2 previous auto-SCTs had a multiple myeloma,
we cannot rule out that double auto-SCT may be a surrogate
marker of this disease.
The studies reporting on acute hepatotoxicity of ATG in
the allo-SCT setting are rare. One case of a young female
patient with Fanconi anemia who received horse ATG as part
of conditioning before transplant was reported in 2007 [8].
The patient developed an asymptomatic elevation of AST
(17.7  ULN) and ALT (12  ULN) at day 5 before transplant.
The ATG was stopped and the liver function tests improved
without recurrence of toxicity after replacement with rabbit
ATG [8]. Recently, 2 cases of female patients who developed a
transient severe transaminase elevation after receiving rab-
bit ATG before allo-SCT were reported. The AST peaked at
1286 and 1212 U/L and the ALT at 991 and 689 U/L. In both
cases, the hepatitis quickly resolved without any complica-
tion [9]. In 2002, the impact of ATG (Fresenius) was studied
by Pihusch et al. [7]. They reported bilirubin levels beyond
the normal range in 22.7% of patients, without change in the
level of transaminases in most patients in contrast to our
study. The different cellular targets used to produce both
rabbit ATG (Jurkat cell line for Fresenius and human thy-
mocytes for Thymoglobulin) may account for differences in
antibodies composition and thus reported toxicities.
Several arguments support the responsibility of ATG in
the reported acute hepatotoxicity. It is indeed very unlikely
that SAH be related to other drugs in conditioning regimens
like ﬂudarabine, i.v. busulfan, or cyclophosphamide. During
the study period, 98 allo-SCTs were performed after a mye-
loablative conditioning with cyclophosphamide 60 mg/kg/
day for 2 days and i.v. busulfan .8 mg/kg  4/day for 4 days
(Bu-Cy; n ¼ 57) or 12-Gy TBI (TBI-Cy, n ¼ 41) with only 1
episode of SAH during a conditioning with Bu-Cy in a patient
with a focal nodular hyperplasia of the liver. We did not
observe any SAH in 33 patients transplanted after the non-
myeloablative conditioning regimen combining ﬂudarabine
(30 mg/m2/day for 3 days) and 2-Gy TBI.
As additional evidence, 46 patients were transplanted
with cord blood units after a RIC regimen combining ﬂu-
darabine (40 mg/m2/day for 5 days), cyclophosphamide (50
mg/kg), and 2-Gy TBI without any episode of SAH. Further-
more, the liver toxicity of Bu-Cy and inverted Cy-Bu was
studied by Cantoni et al. in 2011 [13]. They reported AST and/
or ALT beyond the normal range between day þ10 andday þ30 after transplant and always < 5  ULN. This is in
sharp contrast with our study where SAH was diagnosed at a
median time of 2 days after the start of ATG. Finally, we
cannot incriminate the premedication of ATG or acetamin-
ophen either, because these drugs are commonly used
without ATG in many other circumstances in our unit
without ever observing such acute hepatotoxicity. Moreover,
although severe hepatotoxicity of acetaminophen has almost
exclusively been reported after over-dosages [14], acet-
aminophen was always used in our study at therapeutic
doses (4 g/day).
The mechanisms underlying acute hepatotoxicity of rab-
bit ATG remain undetermined, and the design of our study
precludes any conclusion. However, the rapid reversibility of
the phenomenon reported in our study does not support a
direct toxic effect of ATG on hepatocytes because ATG has a
long mean elimination half-life of 30 days in human plasma
[15,16]. The identiﬁcation of blood systolic pressure< 90mm
Hg during ATG administration as a signiﬁcant risk factor for
SAH raises the hypothesis of a clinical syndrome close to the
shock liver. The shock liver is indeed characterized by a
sudden elevation of AST and ALT in response to cellular
anoxia, followed by a rapid resolution within 7 to 10 days
[17]. This is very similar to the toxicity observed in our study
where the transaminases peaked at a median time of 2 days
after the start of ATG and resolved (<2 ULN) after a median
time of 9 days. Finally, our study also identiﬁes the existence
of 2 previous auto-SCTs as a risk factor for SAH, suggesting
that a heavily pretreated disease might be a favoring condi-
tion of a possible transient ischemic hepatitis caused by
severe hypotension during administration of ATG.
Our study is the ﬁrst to report the incidence of SAH after
administration of ATG (Thymoglobulin) in the allo-SCT
setting, and we believe physicians should be aware of this
common risk to avoid asmuch as possible any other potential
hepatotoxic drug in the immediate post-transplant period
and also because some patients have an increased INR
together with thrombocytopenia and sometimes heparin for
veno-occlusive disease prophylaxis. Our data also suggest
that severe hypotension during ATG administration should
be a warning sign to check liver function tests. This knowl-
edge may help avoid additional hepatotoxicity and prevent
hemorrhagic accidents.
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